

ASX Announcement

5 August 2026

Expiry Of Listed Options (ASX: IMUOE)

Imugene Limited (ASX: IMU) (Imugene or the Company) wishes to advise that 21,698,915 quoted options, exercisable at \$4.012 each (trading under ASX code IMUOE) (Options) will expire at 5pm (AEST) on Monday, 31 August 2026 (Expiry Date).

The Company notes that the Options are substantially “out of the money” and the Company will not be dispatching personalised notices to option holders in accordance with Item 5.3 of Appendix 6A to the ASX Listing Rules.

In accordance with Item 5.2 of Appendix 6A, the Company provides the following information to holders of the Options:

1. the total number of Options on issue is 21,698,915;
2. the number of fully paid ordinary shares in the Company to be issued on the exercise and conversion of the Options is 21,698,915;
3. the exercise price for each Option is \$4.012 each;
4. the due date for payment of the exercise price is 5pm (AEST) on Monday, 31 August 2026 (Expiry Date);
5. if payment is not received by the Expiry Date, the Options will expire unexercised and all rights attaching to the Options will cease;
6. official quotation of the Options on ASX will cease at close of trading on Tuesday, 25 August 2026, being four business days before the Expiry Date;
7. the market price of the Company’s shares on Monday, 3 August 2026, was \$0.084, being the latest available market price of shares on ASX prior to the date of this announcement;
8. during the three months preceding the date of this announcement:
 - the highest market price of the Company’s shares on ASX was \$0.16 on 1 July 2026; and



- the lowest market price of the Company's Shares on ASX was \$0.08 on 30 July 2026; and

9. as at the date of this announcement, there are no underwriting agreements in relation to the Options.

Should you have any queries in relation to this matter please contact the Company's share registry, Automic Group, on +61 2 9698 5414 or Darren Keamy, Company Secretary at shareholderenquiries@imugene.com.

For more information please contact:

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

communications@imugene.com

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

Release authorised by the Company Secretary, Imugene Limited.